| Literature DB >> 33829502 |
Vera van der Velpen1,2, Nadia Rosenberg3, Vanille Maillard1, Tony Teav1, Jean-Yves Chatton3, Hector Gallart-Ayala1, Julijana Ivanisevic1.
Abstract
Levels of nicotine adenine dinucleotide (NAD+) are known to decline with age and have been associated with impaired mitochondrial function leading to neurodegeneration, a key facet of Alzheimer's disease (AD). NAD+ synthesis is sustained via tryptophan-kynurenine (Trp-Kyn) pathway as de novo synthesis route, and salvage pathways dependent on the availability of nicotinic acid and nicotinamide. Whilst being currently investigated as a multifactorial disease with a strong metabolic component, AD remains without curative treatment and important sex differences were reported in relation to disease onset and progression. The aim of this study was to reveal the potential deregulation of NAD+ metabolism in AD with the direct analysis of NAD+ precursors in the mouse brain tissue (wild type (WT) vs. triple transgenic (3xTg) AD), using a sex-balanced design. To this end, we developed a quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, which allowed for the measurement of the full spectrum of NAD+ precursors and intermediates in all three pathways. In brain tissue of mice with developed AD symptoms, a decrease in kynurenine (Kyn) vs. increase in kynurenic acid (KA) levels were observed in both sexes with a significantly higher increment of KA in males. These alterations in Trp-Kyn pathway might be a consequence of neuroinflammation and a compensatory production of neuroprotective kynurenic acid. In the NAD+ salvage pathway, significantly lower levels of nicotinamide mononucleotide (NMN) were measured in the AD brain of males and females. Depletion of NMN implies the deregulation of salvage pathway critical for maintaining optimal NAD+ levels and mitochondrial and neuronal function. This article is protected by copyright. All rights reserved.Entities:
Keywords: 3xTg AD mice model; Alzheimer’s disease; LC-MS; NAD+ metabolism; brain; targeted metabolomics
Year: 2021 PMID: 33829502 DOI: 10.1111/jnc.15362
Source DB: PubMed Journal: J Neurochem ISSN: 0022-3042 Impact factor: 5.372